PIPELINE FLEX EMBOLIZATION DEVICE
Report
- Report Number
- 2029214-2024-00749
- Event Type
- Death
- Date Received
- April 25, 2024
- Date of Event
- August 4, 2023
- Report Date
- April 25, 2024
- Manufacturer
- MICRO THERAPEUTICS, INC. DBA EV3
- Product Code
- OUT
- PMA / PMN Number
- P100018
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- CH
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
A2. REPORTED AGE (55 YEARS) IS THE MEAN AGE OF ALL PATIENT INCLUDED IN THE STUDY. A3A. REPORTED SEX (MALE) IS REPRESENTATIVE OF THE MAJORITY OF PATIENT INCLUDED IN THE STUDY. ADVERSE EVENTS REPORTED IN THE ARTICLE THAT DID NOT HAVE AN OUTCOME OF MORTALITY WILL BE REPORTED SEPARATELY. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.
JIN, H., LV, J., MENG, X., LIU, X., HE, H., & LI, Y. (2023). PIPELINE VERSUS TUBRIDGE IN THE TREATMENT OF UNRUPTURED POSTERIOR CIRCULATION ANEURYSMS. CHINESE NEUROSURGICAL JOURNAL, 9(1). HTTPS://DOI.ORG/10.1186/S41016-023-00337-0 MEDTRONIC REVIEW OF THE LITERATURE ARTICLE FOUND A RETROSPECTIVE STUDY COMPARING THE SAFETY AND CLINICAL EFFICACY OF THE PIPELINE EMBOLIZATION DEVICE (PED) AND NON-MEDTRONIC TUBRIDGE FLOW DIVERTER (TFD) FOR THE TREATMENT OF UNRUPTURED POSTERIOR CIRCULATION ANEURYSMS, WHICH IS OFF-LABEL USE FOR OF THE PED. IT WAS NOTED THAT A TOTAL OF 115 FLOW DIVERTERS WERE USED TO TREAT 107 ANEURYSMS. 55 PATIENTS WERE TREATED WITH PEDS. IT WAS NOTED THAT ALL FLOW DIVERTERS WERE SUCCESSFUL IMPLANTED WITH A 100% TECHNICAL SUCCESS RATE; NO DEVICE MALFUNCTION WAS REPORTED IN THE LITERATURE ARTICLE. A TOTAL OF 9 PATIENTS IN THE STUDY GROUP HAD PROCEDURE-RELATED POST-INTERVENTION ISCHEMIC COMPLICATIONS, 4 OF THESE PATIENTS WERE TREATED WITH PED. THOUGH THE ADVERSE EVENTS WERE FURTHER DESCRIBED IN THE ARTICLE, IT WAS NOT SPECIFIED WHICH EVENTS PERTAINED TO PATIENTS TREATED WITH PED VERSUS PATIENTS TREATED WITH TFD. THE FOLLOWING ADVERSE EVENTS WERE NOTED: ONE PATIENT WAS NOTED TO HAVE A MORTALITY OUTCOME. THE PATIENT, WHO HAD BEEN TREATED FOR A 53MM GIANT ANEURYSM, EXPERIENCED MASS EFFECT, LOSS OF CONSCIOUSNESS, AND COMA. THE PATIENT DIED OF "SUDDEN CARDIOPULMONARY ARREST 1 DAY AFTER THE PROCEDURE."
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1468329 | PIPELINE FLEX EMBOLIZATION DEVICE | INTRACRANIAL ANEURYSM FLOW DIVERTER | OUT | MICRO THERAPEUTICS, INC. DBA EV3 | NV UNK FLEX | UNKNOWN |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 55 YR | Male | Death |